The Relationship Between Long Non-Coding RNA Expressions and Ponatinib in Breast Cancer
Yıl: 2019 Cilt: 4 Sayı: 2 Sayfa Aralığı: 125 - 130 Metin Dili: İngilizce DOI: 10.5152/cjms.2019.819 İndeks Tarihi: 10-09-2020
The Relationship Between Long Non-Coding RNA Expressions and Ponatinib in Breast Cancer
Öz: BACKGROUND/AIMSBreast cancer is the most common type of cancer in women and is among the leading causes of cancer-related deaths. Long non-coding RNAs (lncRNAs) play significant roles in cell proliferation, transcriptional regulation, cell cycle progression, apoptosis, carcinogenesis, and metastasis. Studies have shown that ponatinib has an antiproliferative effect in some types of cancer. The aim of the present study was to evaluate the effect of ponatinib on cytotoxicity and to determine changes in lncRNA expression levels with the use of ponatinib treatment in estrogen receptor (ER)-independent MDA-MB-231 and ER-dependent MCF-7 breast cancer cells.MATERIAL and METHODSThe cytotoxic effects of ponatinib were determined by using the xCELLigence system. Changes in lncRNA expression profiles were determined using quantitative reverse transcription polymerase chain reaction to investigate the antiproliferative roles of ponatinib in breast cancer.RESULTSIn human breast adenocarcinoma cell lines (MCF-7 and MDA-MB-231), the IC50 doses of ponatinib were determined to be 4.59 μM (72 h) and 1.41 μM (48 h), respectively. After ponatinib treatment, we observed changes in lncRNA expression profiles in ER-independent MDA-MB-231 and ER-dependent MCF-7 breast cancer cells compared with the control group.CONCLUSIONThe changes in the lncRNA expression profiles and the anti-cancer agent of ponatinib play roles in the definition of therapeutic target for new approach in breast cancer.
Anahtar Kelime: Belge Türü: Makale Makale Türü: Araştırma Makalesi Erişim Türü: Erişime Açık
- 1. Kilic N, Aras S, Cansaran-Duman D. Determination of Vulpinic Acid Effect on Apoptosis and mRNA Expression Levels in Breast Cancer Cell Lines. Anticancer Agents Med Chem 2018; 18: 2032-41. [CrossRef]
- 2. Kiliç N, Islakoglu YO, Buyuk İ, Gur-Dedeoglu B, Cansaran-Duman D. Determination of Usnic Acid Responsive miRNAs in Breast Cancer Cell Lines. Anticancer Agents Med Chem 2018. doi: 10.2174/1871520618666181112120142 [Epub ahead of print]. [CrossRef]
- 3. Miller GD, Bruno BJ, Lim CS. Resistant mutations in CML and Ph(+)ALL - role of ponatinib. Biologics 2014; 8: 243-54. [CrossRef]
- 4. Gozgit JM, Wong MJ, Moran L, Wardwell S, Mohemmad QK, Narasimhan NI, et al. Ponatinib (AP24534), a multitargeted panFGFR inhibitor with activity in multiple FGFR-amplified or mutated cancer models. Mol Cancer Ther 2012; 11: 690-9. [CrossRef]
- 5. Bauer K, Berger D, Zielinski CC, Valent P, Grunt TW. Hitting two oncogenic machineries in cancer cells: cooperative effects of the multi-kinase inhibitor ponatinib and the BET bromodomain blockers JQ1 or dBET1 on human carcinoma cells. Oncotarget 2018; 9: 26491-506. [CrossRef]
- 6. Guttman M, Amit I, Garber M, French C, Lin MF, Feldser D, et al. Chromatin signature reveals over a thousand highly conserved large non-coding RNAs in mammals. Nature 2009; 458: 223-7. [CrossRef]
- 7. Kung JT, Colognori D, Lee JT. Long noncoding RNAs: past, present, and future. Genetics 2013; 193: 651-69. [CrossRef]
- 8. Li J, Liu R, Tang S, Feng F, Wang X, Qi L et al. The effect of long noncoding RNAs HOX transcriptantisense intergenic RNA single‐nucleotidepolymorphisms on breast cancer, cervical cancer, andovarian cancer susceptibility: A meta‐analysis. J Cell Biochem 2018. doi: 10.1002/jcb.27975. [Epub ahead of print]. [CrossRef]
- 9. Su JC, Hu XF. Long non‑coding RNA HOXA11‑AS promotes cell proliferation and metastasis in human breast cancer. Mol Med Rep 2017; 16: 4887-94. [CrossRef]
- 10. Russo F, Fiscon G, Conte F, Rizzo M, Paci P, Pellegrini M. Interplay Between Long Noncoding RNAs and MicroRNAs in Cancer. Methods Mol Biol 2018; 1819: 75-92. [CrossRef]
- 11. Liu H, Li J, Koirala P, Ding X, Chen B, Wang Y, et al. Long non-coding RNAs as prognostic markers in human breast cancer. Oncotarget 2016; 7: 20584-96. [CrossRef]
- 12. Soudyab M, Iranpour M, Ghafouri-Fard S. The Role of Long Non-Coding RNAs in Breast Cancer. Arch Iran Med 2016; 19: 508-17.
- 13. Sun H, Wang G, Peng Y, Zeng Y, Zhu QN, Li TL, et al. H19 lncRNA mediates 17β-estradiol-induced cell proliferation in MCF-7 breast cancer cells. Oncol Rep 2015; 33: 3045-52. [CrossRef]
- 14. Raveh E, Matouk IJ, Gilon M, Hochberg A. The H19 Long non-coding RNA in cancer initiation, progression and metastasis – a proposed unifying theory. Mol Cancer 2015; 14: 184. [CrossRef]
- 15. Yoshimura H, Matsuda Y, Yamamoto M, Michishita M, Takahashi K, Sasaki N, et al. Reduced expression of the H19 long non-coding RNA inhibits pancreatic cancer metastasis. Lab Invest 2018; 98: 814-24. [CrossRef]
- 16. Chen Q, Sun T, Wang F, Gong B, Xie W, Ma M, et al. Long noncoding RNA IGF2AS is acting as an epigenetic tumor suppressor in human prostate cancer. Urology 2019; 124: e1-310. [CrossRef]
- 17. Wang Y, Hu Y, Wu G, Yang Y, Tang Y, Zhang W, et al. Long noncoding RNA PCAT-14 induces proliferation and invasion by hepatocellular carcinoma cells by inducing methylation of miR-372. Oncotarget 2017; 8: 34429-41. [CrossRef]
- 18. Qiao L, Liu X, Tang Y, Zhao Z, Zhang J, Feng Y. Down regulation of the long non-coding RNA PCAT-1 induced growth arrest and apoptosis of colorectal cancer cells. Life Sci 2017; 188: 37-44. [CrossRef]
- 19. Iranpour M, Soudyab M, Geranpayeh L, Mirfakhraie R, Azargashb E, Movafagh A, et al. Expression analysis of four long noncoding RNAs in breast cancer. Tumour Biol 2016; 37: 2933-40. [CrossRef]
- 20. Farhangian P, Jahandoost S, Mowla SJ, Khalili M. Differential expression of long non-coding RNA SOX2OT in gastric adenocarcinoma. Cancer Biomark 2018; 23: 221-5. [CrossRef]
- 21. Singh R, Gupta SC, Peng WX, Zhou N, Pochampally R, Atfi A, el al. Regulation of alternative splicing of Bcl-x by BC200 contributes to breast cancer pathogenesis. Cell Death Dis 2016; 7: e2262. [CrossRef]
- 22. Wu DI, Wang T, Ren C, Liu L, Kong D, Jin X, et al. Downregulation of BC200 in ovarian cancer contributes to cancer cell proliferation and chemoresistance to carboplatin. Oncol Lett 2016; 11: 1189-94. [CrossRef]
- 23. Li Y, Zhang D, Yu K, Hu Y, Wu Q, Qian F, et al. CMPD1 inhibited human gastric cancer cell proliferation by inducing apoptosis and G2/M cell cycle arrest. Biol Res 2018; 51: 11. [CrossRef]
- 24. Fang C, He W, Xu T, Dai J, Xu L, Sun F. Upregulation of lncRNA DGCR5 correlates with better prognosis and inhibits bladder cancer progression via transcriptionally facilitating P21 expression. J Cell Physiol 2019; 234: 6254-62. [CrossRef]
- 25. Zou H, Wu LX, Yang Y, Li S, Mei Y, Liu YB, et al. lncRNAs PVT1 and HAR1A are prognosis biomarkers and indicate therapy outcome for diffuse glioma patients. Oncotarget 2017; 8: 78767-80. [CrossRef]
- 26. J Li, M Zhang, G An, Q Ma. LncRNA TUG1 acts as a tumor suppressor in human glioma by promoting cell apoptosis. Exp Biol Med 2016; 241: 644-9. [CrossRef]
- 27. Zhang EB, Yin DD, Sun M, Kong R, Liu XH, You LH, et al. P53-regulated long non-coding RNA TUG1 affects cell proliferation in human non-small cell lung cancer, partly through epigenetically regulating HOXB7 expression. Cell Death Dis 2014; 5: e1243. [CrossRef]
- 28. Fan S, Yang Z, Ke Z, Huang K, Liu N, Fang X, et al. Downregulation of the long non-coding RNA TUG1 is associated with cell proliferation, migration, and invasion in breast cancer. Biomed Pharmacother 2017; 95: 1636-43. [CrossRef]
- 29. Li JY, Ma X, Zhang CB. Overexpression of long non-coding RNA UCA1 predicts a poor prognosis in patients with esophageal squamous cell carcinoma. Int J Clin Exp Pathol 2014; 7: 7938-44.
- 30. Ren S, Liu Y, Xu W, Sun Y, Lu J, Wang F, et al. Long noncoding RNA MALAT-1 is a new potential therapeutic target for castration resistant prostate cancer. J Urol 2013; 190: 2278-87. [CrossRef]
- 31. Li T, Xie J, Shen C, Cheng D, Shi Y, Wu Z, et al. Upregulation of long noncoding RNA ZEB1-AS1 promotes tumor metastasis and predicts poor prognosis in hepatocellular carcinoma. Oncogene 2016; 35: 1575-84. [CrossRef]
- 32. Lan T, Chang L, Wu L, Yuan Y. Downregulation of ZEB2-AS1 decreased tumor growth and metastasis in hepatocellular carcinoma. Mol Med Rep 2016; 14: 4606-12. [CrossRef]
- 33. Sun L, Li Y, Yang B. Downregulated long non-coding RNA MEG3 in breast cancer regulates proliferation, migration and invasion by depending on p53's transcriptional activity. Biochem Biophys Res Commun 2016; 478: 323-9. [CrossRef]
- 34. Ghaforui-Fard S, Taheri M. Nuclear Enriched Abundant Transcript 1 (NEAT1): A long non-coding RNAwith diverse functions in tumorigenesis. Biomed Pharmacother 2018; 111: 51-9. [CrossRef]
| APA | OKCANOĞLU T, Kayabasi C, YILMAZ SUSLUER S, Gunduz C (2019). The Relationship Between Long Non-Coding RNA Expressions and Ponatinib in Breast Cancer. , 125 - 130. 10.5152/cjms.2019.819 |
| Chicago | OKCANOĞLU Tuğçe BALCI,Kayabasi Cagla,YILMAZ SUSLUER SUNDE,Gunduz Cumhur The Relationship Between Long Non-Coding RNA Expressions and Ponatinib in Breast Cancer. (2019): 125 - 130. 10.5152/cjms.2019.819 |
| MLA | OKCANOĞLU Tuğçe BALCI,Kayabasi Cagla,YILMAZ SUSLUER SUNDE,Gunduz Cumhur The Relationship Between Long Non-Coding RNA Expressions and Ponatinib in Breast Cancer. , 2019, ss.125 - 130. 10.5152/cjms.2019.819 |
| AMA | OKCANOĞLU T,Kayabasi C,YILMAZ SUSLUER S,Gunduz C The Relationship Between Long Non-Coding RNA Expressions and Ponatinib in Breast Cancer. . 2019; 125 - 130. 10.5152/cjms.2019.819 |
| Vancouver | OKCANOĞLU T,Kayabasi C,YILMAZ SUSLUER S,Gunduz C The Relationship Between Long Non-Coding RNA Expressions and Ponatinib in Breast Cancer. . 2019; 125 - 130. 10.5152/cjms.2019.819 |
| IEEE | OKCANOĞLU T,Kayabasi C,YILMAZ SUSLUER S,Gunduz C "The Relationship Between Long Non-Coding RNA Expressions and Ponatinib in Breast Cancer." , ss.125 - 130, 2019. 10.5152/cjms.2019.819 |
| ISNAD | OKCANOĞLU, Tuğçe BALCI vd. "The Relationship Between Long Non-Coding RNA Expressions and Ponatinib in Breast Cancer". (2019), 125-130. https://doi.org/10.5152/cjms.2019.819 |
| APA | OKCANOĞLU T, Kayabasi C, YILMAZ SUSLUER S, Gunduz C (2019). The Relationship Between Long Non-Coding RNA Expressions and Ponatinib in Breast Cancer. Cyprus Journal of Medical Sciences, 4(2), 125 - 130. 10.5152/cjms.2019.819 |
| Chicago | OKCANOĞLU Tuğçe BALCI,Kayabasi Cagla,YILMAZ SUSLUER SUNDE,Gunduz Cumhur The Relationship Between Long Non-Coding RNA Expressions and Ponatinib in Breast Cancer. Cyprus Journal of Medical Sciences 4, no.2 (2019): 125 - 130. 10.5152/cjms.2019.819 |
| MLA | OKCANOĞLU Tuğçe BALCI,Kayabasi Cagla,YILMAZ SUSLUER SUNDE,Gunduz Cumhur The Relationship Between Long Non-Coding RNA Expressions and Ponatinib in Breast Cancer. Cyprus Journal of Medical Sciences, vol.4, no.2, 2019, ss.125 - 130. 10.5152/cjms.2019.819 |
| AMA | OKCANOĞLU T,Kayabasi C,YILMAZ SUSLUER S,Gunduz C The Relationship Between Long Non-Coding RNA Expressions and Ponatinib in Breast Cancer. Cyprus Journal of Medical Sciences. 2019; 4(2): 125 - 130. 10.5152/cjms.2019.819 |
| Vancouver | OKCANOĞLU T,Kayabasi C,YILMAZ SUSLUER S,Gunduz C The Relationship Between Long Non-Coding RNA Expressions and Ponatinib in Breast Cancer. Cyprus Journal of Medical Sciences. 2019; 4(2): 125 - 130. 10.5152/cjms.2019.819 |
| IEEE | OKCANOĞLU T,Kayabasi C,YILMAZ SUSLUER S,Gunduz C "The Relationship Between Long Non-Coding RNA Expressions and Ponatinib in Breast Cancer." Cyprus Journal of Medical Sciences, 4, ss.125 - 130, 2019. 10.5152/cjms.2019.819 |
| ISNAD | OKCANOĞLU, Tuğçe BALCI vd. "The Relationship Between Long Non-Coding RNA Expressions and Ponatinib in Breast Cancer". Cyprus Journal of Medical Sciences 4/2 (2019), 125-130. https://doi.org/10.5152/cjms.2019.819 |
